Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products announced successful completion of the nonclinical development phase of Focal Medical’s Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003).
The Lubrizol Corporation announces the new EU food-grade approval for Carbopol® Polymers. The approval in the EU will enable nutraceutical manufacturers the ability to differentiate their portfolio and create unique new product claims.
Celltrion Group announced that the merger agreement between Celltrion, Inc. was approved at the extraordinary general meeting of shareholders (“EGM”) of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.
Seegene's eco-friendly shipping box is composed of 12-paper layers, biodegradable films, recycled PET packaging, a vacuum insulation panel, dry ice, and ice packs. The materials are either 100% renewable or certified as "green" via organizations such as the Forest Stewardship Council (FSC) and the Ministry of Environment in Korea.
TriasMD, a musculoskeletal management company and parent of the DISC Surgery Centers, has announced its acquisition of Walnut Creek-based Pinnacle Surgery Center ("Pinnacle").
Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3.
A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.
Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen's innovative CAR-GPC3 T-cell therapy.
Cambrex announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.